Assessment of Cell-mediated Immunity to Malignant Mesothelioma by Microcytotoxicity Tests
Overview
Affiliations
Cell cultures were established from pleural effusions of patients with pleural mesothelioma, and peripheral mononuclear effector cells were tested for cytotoxicity against these cells by means of microcytotoxicity assay. Effector cells were obtained from normal healthy donors and from persons exposed occupationally to asbestos, including apparently healthy persons, patients with benign pleural conditions and patients with malignant mesothelioma. The overall incidence of cytotoxicity was low, and there was no evidence of increased cytotoxicity in mesothelioma patients or other asbestos-exposed donors. It is concluded that little or no tumour-directed cell-mediated immunity is detectable against malignant mesothelioma by microcytotoxicity methods.
Brown D, Wagner J, Wagner M Br J Cancer. 1980; 42(5):797-801.
PMID: 7459217 PMC: 2010543. DOI: 10.1038/bjc.1980.316.
Diffuse malignant mesothelioma: a review.
Rom W, Lockey J West J Med. 1982; 137(6):548-54.
PMID: 6761970 PMC: 1274231.
Stevens R, Cole D, Cheng H, Hodge J, Will L Environ Health Perspect. 1983; 51:91-6.
PMID: 6641663 PMC: 1569267. DOI: 10.1289/ehp.835191.
Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.
Embleton M, Ransom J, McIllmurray M, Reeves W Br J Cancer. 1978; 37(4):497-504.
PMID: 565645 PMC: 2009553. DOI: 10.1038/bjc.1978.77.
Benign pleural lesion and malignant mesothelioma.
Klima M, Gyorkey F Virchows Arch A Pathol Anat Histol. 1977; 376(3):181-93.
PMID: 145715 DOI: 10.1007/BF00432395.